名为SAINTI(StrokeAcuteIschemlcNXY059Treatment) 的Ⅲ期临床实验数据表明,NXY-059对缺血性中风造成的神 经损害有一定疗效。这项实验在全球约24个国家和地区的 158个临床研究中心同步展开,为双盲、随机的安慰剂对照 实验设计,参加人数超过1700名。有关的研究及结果已经 ...
急性缺血性卒中NXY治疗(Stroke—AcuteIschemicNXYTreatment,SAINTI)试验是 一项随机双盲安慰剂 对照研究,1722例急性缺血性卒中患者随机分组,在发病后6h内接受为期72h的 安慰剂或NXY-059静脉 滴注.主要转归指标为90d时的残疾状况,以改良Rankin量表 (modifiedRankinscale,mRS)评分进行衡量,0 分表示不遗留任何残疾症状,5分...
S A N F R A N C I S C O -- In the largest ran- domized acute stroke neuroprotection tri- al to date, the investigational free-radical trapping neuroprotectant NXY-059 failed to provide any benefit over placebo for improving stroke outcomes, despite promising data from an earlier trial,...
Acute ischemic stroke patients receiving NXY-059 may also be exposed to diuretics for treatment of heart failure or hypertension. NXY-059 and furosemide are partly eliminated by active tubular secretion via an organic anion transporter. This double-blind, randomized, crossover, placebo-controlled ...
In a post hoc analysis of patients who also received Alteplase, NXY-059 was associated with a lower incidence of hemorrhagic stroke transformation (P = .001) and a lower incidence of symptomatic intercranial hemorrhage (P = .036). Comment: This study shows a modest but statistically ...
In a post hoc analysis of patients who also received Alteplase, NXY-059 was associated with a lower incidence of hemorrhagic stroke transformation (P = .001) and a lower incidence of symptomatic intercranial hemorrhage (P = .036). Comment: This study shows a modest but statistically ...
摘要: 动物实验证实,自由基捕获剂NXY-059能缩小急性脑缺血的梗死体积并改善神经功能,是一种符合卒中治疗学术产业圆桌会议(Stroke Therapy Academic Industry Roundtable,STAIR)标准的神经保护剂.据最近的N Engl J Med报道,急性缺血性卒中后早期给予NXY-059能显著改善患者转归.关键词:...
Development of the Nitrone-Based Spin Trap Agent NXY-059 to Treat Acute Ischemic Stroke. CNS Drug Rev. 2003 Fall; 9 (3):253–262.Lapchak PA, Araujo DM. Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke. CNS Drug Rev. 2003;9(3):253–62....
NXY-059 is a novel free radicaltrapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. It is the first neuroprotectant to demonstrate a reduction in global disability in a phase III clinical trial, as measured by the modified Ranki...
Stroke. 200 1,32( 1 ) : 1 9 0 ～ 8 — 10 Lapehak PA .Song D ,W ei J ,et aL Exp Neura1.2004 .188( 2) :2 79 ～ 8 j 1l Lapchak PA .A raujo D M ,Song D ,et a1.Stroke.2002 ,33 ( 5 j :t 4 1 1 ～ 5 ...